We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




New Breast Cancer Susceptibility Genes to Pave Way for Risk Prediction Test

By LabMedica International staff writers
Posted on 21 Aug 2023

Genetic tests for breast cancer currently focus on a limited number of genes, including BRCA1, BRCA2, and PALB2, but this scope only accounts for a small part of the overall genetic risk for the disease. More...

This has led researchers to believe that other risk-associated genes are yet to be discovered. Now, a large-scale international collaborative study has identified new genes linked to breast cancer that could eventually be included in tests to detect women at an elevated risk of the disease.

The study led by researchers from Université Laval (Québec, Canada) and the University of Cambridge (Cambridge, UK) has found evidence for at least four new breast cancer risk genes, and possibly more. These newly-discovered genes deepen medical understanding of the genetic risk factors for breast cancer and could improve risk prediction. By identifying women with a higher likelihood of developing the disease, there is potential for improving breast screening methods, risk reduction strategies, and clinical management practices. In addition, the discovery of these new genes sheds light on the biological processes that lead to cancer development, possibly paving the way for new treatment options.

What sets this study apart is the extensive genetic data utilized in the analysis. The research included an examination of genetic changes across all genes in a sample of 26,000 women with breast cancer and 217,000 without the disease, encompassing participants from eight countries in Europe and Asia. The goal is to incorporate this newfound information into a comprehensive risk prediction tool that health professionals worldwide currently use. However, before these discoveries can be implemented in a clinical environment, the researchers have recognized the need to validate the results with further datasets for which the team is presently undertaking a large-scale international effort.

"Improving genetic counseling for high-risk women will promote shared decision-making regarding risk reduction strategies, screening and determination of treatment options," said Professor Jacques Simard of Université Laval. “Although most of the variants identified in these new genes are rare, the risks can be significant for women who carry them. For example, alterations in one of the new genes, MAP3K1, appear to give rise to a particularly high risk of breast cancer.”

Related Links:
Université Laval 
University of Cambridge 


Gold Member
Collection and Transport System
PurSafe Plus®
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Sperm Quality Analyis Kit
QwikCheck Beads Precision and Linearity Kit
Anterior Nasal Specimen Collection Swabs
53-1195-TFS, 53-0100-TFS, 53-0101-TFS, 53-4582-TFS
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Industry

view channel
Image: The LIAISON NES molecular point-of-care platform (Photo courtesy of Diasorin)

Diasorin and Fisher Scientific Enter into US Distribution Agreement for Molecular POC Platform

Diasorin (Saluggia, Italy) has entered into an exclusive distribution agreement with Fisher Scientific, part of Thermo Fisher Scientific (Waltham, MA, USA), for the LIAISON NES molecular point-of-care... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.